Neurology Center of North Orange County

Fullerton, California 92835-1040

5 studies enrolling now · 45 studies all time

What they study most

AD, Agitation, Agitation and Aggression in Alzheimer's Disease, Alzheimer Disease, Alzheimer Disease 1, Alzheimer Disease 10, Alzheimer Disease 11, Alzheimer Disease 12, Alzheimer Disease 13, Alzheimer Disease 14, Alzheimer Disease 15, Alzheimer Disease 16

Studies at this site

• A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease — Recruiting now
• Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis — Recruiting now
• A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults — Recruiting now
• Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type — Recruiting now
• A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE — Running, not enrolling
• A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults — Running, not enrolling
• A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults — Running, not enrolling
• A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease — Running, not enrolling
• A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease — Running, not enrolling
• A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments — Completed
• A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (HOPE Study) — Running, not enrolling
• A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease — Running, not enrolling
• A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ) — Completed
• A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease — Running, not enrolling
• A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3) — Running, not enrolling
• A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD) — Running, not enrolling
• Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease — Stopped early
• A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) — Running, not enrolling
• Open-label Extension for Phase 3 Clinical Trials of Simufilam — Stopped early
• A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease — Stopped early
• A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205 — Stopped early
• Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis — Completed
• A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4) — Completed
• A Study to Evaluate Treatment Satisfaction With Erenumab in Participants With Migraine — Completed
• A Study to Evaluate the Safety, Tolerability, and Efficacy of Long-Term Gantenerumab Administration in Participants With Alzheimer's Disease (AD) — Stopped early
• Extension to a Pivotal Study of Sensory Stimulation in Alzheimer's Disease (OLE Hope Study, CA-0015) — Enrolling by invitation
• Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD) — Stopped early
• Study of BHV-4157 in Alzheimer's Disease — Completed
• SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study — Completed
• A Study of Aducanumab in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Participants With Asymptomatic Amyloid-Related Imaging Abnormalities — Stopped early
• 221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease — Stopped early
• 12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine — Completed
• Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis — Completed
• A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease — Completed
• A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia — Stopped early
• Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo — Stopped early
• An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine — Completed
• Multiple Dose Safety Study of NPT088 in Patients With Mild to Moderate Probable Alzheimer's Disease — Completed
• Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease (US202) — Completed
• Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine — Completed
• Registry of Amyloid Positive Patients for Alzheimer's Disease Drug Research Trials — Completed
• A Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy — Completed
• A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease — Stopped early
• Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier) — Completed
• Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier) — Completed